REC-4881 Cuts Larger, High-Risk Polyps Across GI Tract in Phase 2 FAP Data
RXRX sits 38% above its 52-week low of $2.77.
Summary
Recursion presented new TUPELO Phase 2 analyses at the CGA-IGC meeting showing REC-4881 reduced polyp burden in the lower GI tract and shrank the larger polyps that drive most FAP surgeries. In the lower GI, 9 of 11 patients (82%) had reductions after 12 weeks, with a 50% median drop; six of eight patients had fewer polyps larger than 5 mm, and four saw counts fall by at least 80%. This builds on the upper GI results disclosed October 15, which is also when the company priced a $200M stock offering at $3.25 a share. Durability looks solid: 85% of patients remained below baseline at Week 25, 12 weeks off treatment, and no new safety signals appeared across 26 safety-evaluable patients. Management says the priority is aligning with the FDA on a registrational path, with a trial targeted for the second half of 2027 and more details expected later this year.
At the time of this announcement, RXRX was trading at $3.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $2.77 to $5.76. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.